We will additionally discuss recent findings that identify Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2), an AR-regulated gene with additional roles in bone remodeling and inflammation, as a novel therapeutic target to inhibit PCa growth and prevention of ADT-associated bone loss. The gene discussed is AR; the disease is posterior cortical atrophy.